argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
15 sep 2016 - 07:00
Statutaire naam
argenx SE
Titel
argenx to host inaugural R&D day and webcast on September 22, 2016
Bericht
Breda, the Netherlands / Ghent, Belgium, 15 September 2016 - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it will host its inaugural R&D day on Thursday, September 22, 2016 from 9:00 a.m. -12:00 p.m. ET in New York City.
During the event, members of argenx management will present updates to the Company's pipeline of differentiated antibodies including ARGX-113 for severe autoimmune diseases and ARGX-110 for oncology indications.
Datum laatste update: 27 juli 2024